Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors PD1 and PD-L1

Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors PD1 and PD-L1

US Patent 11919938 · Granted Mar 5, 2024

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Composition comprising recombinant Gplbα receptor protein2025
Composition comprising recombinant Gplbα receptor protein2025
Lateral flow immunoassays for the detection of antibodies against biological dru2025
Composition comprising recombinant GPlbα receptor protein2023
Composition comprising recombinant GPlbα receptor protein2023
Compositions, methods and/or kits comprising a recombinant human CD38- extracell2023
Compositions, methods and/or kits comprising a recombinant human CD38- extracell2023
Lateral flow immunoassays for the detection of antibodies against biological dru2020
Method to optimize the treatment of patients with biological drugs2019
Antibodies against Clostridium difficile2018
Clostridium difficile antibodies2018
Blocking reagent compositions and methods of making and using the same2017